The role of vascular epithelial growth factor receptor–tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials. (December 2013)

• Record Type: Journal Article
• Authors: Li, Jianwen; Huang, Shengchao; Zheng, Wanting; Ding, Hongfei; Zhang, Yuanqi; Huang, Shuichuan; Zhang, Zhi; Chen, Baoying; Liang, Zhongzeng; He, Gan; Xiao, Xiongsheng; Li, Siyi; Xu, Tuo; Chen, Xiaodong
• Is Part Of: Current medical research and opinion. Volume 29:Number 12(2013:Dec.)
• Page Start: 1691
• Page End: 1699
• Publication Date: 2013-12
• Subjects: Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1185/03007995.2013.836080
• Languages: English
• ISSNs: 0300-7995

Abstract

<abstract> <title>Abstract</title> <sec id="ss1"> <title>Aim:</title> <p>To perform a systematic review and meta-analysis of randomized controlled trials to determine the efficacy and toxicity of approved vascular epithelial growth factor receptor–tyrosine kinase inhibitors (VEGFR-TKIs) in advanced breast cancer.</p> </sec> <sec id="ss2"> <title>Methods:</title> <p>A comprehensive literature search for studies published up to August 2013 was performed. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>Twelve randomized controlled trials involved 3256 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that VEGFR-TKI therapy significantly improved ORR (RR 1.14, 95% CI: 1.03–1.28, <italic>p</italic> = 0.016), but it did not translate into benefits in PFS (HR 0.99, 95% CI: 0.81–1.22, <italic>p</italic> = 0.93) and OS (HR 1.11, 95% CI 0.99–1.24, <italic>p</italic> = 0.084) when compared to non-VEGFR-TKI therapy. Additionally, a higher incidence of grade 3 or 4 anemia, neutropenia, thrombocytopenia, diarrhea, hand-foot syndrome and fatigue was observed in VEGFR-TKI-based therapy.</p> </sec> <sec id="ss4"> <title>Conclusions:</title> <p>The VEGFR-TKI-based therapy offered a significant improvement in ORR in patients with advanced breast cancer but did not benefit PFS and OS. With present available data from randomized clinical trials, we were still unable to clearly set the role of VEGFR-TKIs in the treatment of metastatic breast cancer (MBC).</p> </sec> </abstract>